Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. HALO | 0.00 |
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:
HALO) with a Equal-Weight and raises the price target from $75 to $95.